ArticlePloS one2017
Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2024Pooled it
- The role of testosterone, the androgen receptor, and hypothalamic-pituitary-gonadal axis in depression in ageing Men.Reviews in endocrine & metabolic disorders · 2022Review
- Relationships between Plasma Concentrations of Testosterone and Dihydrotestosterone and Geriatric Depression Scale Scores in Men and Women Aged 60-65 Years-A Multivariate Approach with the Use of Quade's Test.International journal of environmental research and public health · 2022Article
- Analysis of Brain Functions in Men with Prostate Cancer under Androgen Deprivation Therapy: A One-Year Longitudinal Study.Life (Basel, Switzerland) · 2021Article
- Use of psycho-oncological services by prostate cancer patients: A multilevel analysis.Cancer medicine · 2020Observational
- Article
- Associations between testosterone and metabolic syndrome in depressed and non-depressed older men and women.International journal of geriatric psychiatry · 2019Article
- Spirit-Quieting Traditional Chinese Medicine may Improve Survival in Prostate Cancer Patients with Depression.Journal of clinical medicine · 2019Article
- Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.Prostate cancer and prostatic diseases · 2018Article
- Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer.Journal of pain and symptom management · 2018Observational
- No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study.Therapeutics and clinical risk management · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen deprivation therapy (ADT) results in testosterone suppression, a hypothesized mechanism linking ADT to depressive symptoms. This study investigated the relationship between ADT and the risk of subsequently being diagnosed with depressive disorder (DD) during a 3-year follow-up period. The patient sample for this population-based, retrospective cohort study was retrieved from the Taiwan Longitudinal Health Insurance Database 2005. We included all 1714 patients aged over 40 years with a first-time diagnosis of prostate cancer (PC) during 2001 to 2010 who did not have an orchiectomy. Among them, we defined 868 patients who received ADT during the 3-year follow-up period as the study group, and 846 patients who did not receive ADT as the comparison group. The incidence rates of DD per 1000 person-years were 13.9 (95% confidence interval (CI): 9.5~19.6) and 6.7 (95% CI: 3.7~11.0), respectively. Cox proportional hazard regressions showed that the adjusted hazard ratio for DD for ADT recipients was 1.93 (95% CI: 1.03~3.62) relative to the comparison group. This study presents epidemiological evidence of an association between ADT and a subsequent DD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.